An M&A Monday

It was a busy day for dealmakers, so let’s recap some of the biggest movers. 🀩

After months of searching for a deal, Vince McMahon’s World Wrestling Entertainment (WWE) has agreed to merge with the UFC as part of a deal with Endeavor Group. The deal values WWE at $9.3 billion and Endeavor’s asset UFC at $12.1 billion. πŸ’°

Ari Emanuel’s Endeavor will control a majority 51% stake in the new company, while WWE shareholders will own the remaining 49%. Endeavor will appoint six members, and WWE will appoint five to the eleven-person board of directors.Β Finally, the newly-formed company will trade on the New York Stock Exchange under the ticker symbol $TKO.

As for management, Ari Emanuel will act as CEO for both Endeavor and the newly-formed company. Vince McMahon will serve as executive chairman, and Endeavor President and COO Mark Shapiro will serve those roles at both companies. Dana White will remain president of UFC, and WWE CEO Nick Khan will remain president of the wrestling business. πŸ‘¨β€πŸ’Ό

Real estate investment trust Extra Space Storage is acquiring Life Storage in a $12.7 billion all-stock deal. The combined company will become the largest U.S. self-storage operator by store count. Extra Space and Life Storage shareholders will own about 65% and 35% of the combined company. πŸ“¦

The deal comes shortly after Life Storage had turned down an $11 billion all-stock takeover bid from Public Storage. While the self-storage business has cooled off from its pandemic-level highs, it remains a significant asset class for investors.

Copper and zinc miner Teck Resources officially rejected an unsolicited $22.5 billion takeover bid from Glencore PLC. Teck executives say they’re hesitant to expose their shareholders to Glencore’s large thermal coal business, unwanted oil trading business, and significant jurisdictional risk. They said that the company is not currently contemplating a sale and is instead focused on its proposed restructuring plan set for a shareholder vote on April 26. βš’οΈ

Meanwhile, Glencore said this proposal was a merger and not a takeover and that it would not increase its offer price. This is the second time talks between the companies have broken down, with the first occurring in 2020.

The Federal Trade Commission (FTC) has ordered Illumina to divest its $7.1 billion acquisition of cancer test developer Grail. The regulator said the deal would stifle innovation and competition in the U.S. cancer market. The ruling comes months after an administrative judge dismissed the regulator’s initial challenge. It’s likely a welcome sign for activist investor Carl Icahn and other shareholders, who looked down on the controversial deal when it was originally announced. 🚫

Shares of Cineworld, which owns Regal Cinemas, fell 50% after stopping its efforts to sell its U.S., U.K., and Irish businesses. The world’s second-largest movie theatre chain is also restructuring its debt with lenders to help it exit bankruptcy. However, the deal does not provide any recovery of funds for shareholders. πŸŽ₯

The board of HSBC unanimously recommended that shareholders vote against proposals to restructure the bank and pay fixed dividends. Executives and the board say breaking up the bank by restructuring or spinning off its Asia business would create “a major period of uncertainty” for clients and other stakeholders. πŸ—³οΈ

And lastly, BioNTech signed a licensing agreement with Duality Biologics for two antibody-drug conjugates (ADC) assets for solid tumors. The agreement is potentially worth $1.5 billion, plus royalties on net sales, in addition to the $170 million upfront payment. 🀝

More in   M&A

View All

Walgreens Gets The Boot

It’s tough being part of the U.S. stock market’s largest indexes. With thousands of individual stocks to choose from, if any one component isn’t performing, it’s simply replaced by something else. πŸ”€

In other words, everyone is replaceable. That’s the harsh truth that Walgreens is facing today after discovering Amazon is replacing it in the Dow Jones Industrial Average. πŸ”€

Read It

Biotech Builds Buyout Momentum

It was another busy Monday of M&A activity in the biotech and healthcare space, with more expected during this week’s annual JPMorgan Healthcare Conference. Let’s quickly recap today’s deals. πŸ“

Johnson & Johnson will acquire cancer drug developer Ambrx Biopharma for $2 billion in cash. Ambrx is aiming to target multiple cancers with drugs called antibody-drug conjugates, or ADCs, which are described by researchers as “guided missiles” to directly target and kill cancer cells while limiting damage to healthy cells. 🎯

Read It

Ever-Unpredictable Elon Musk Announces Temporary Hold on Twitter Buyout… on Twitter

In a master stroke of irony, Elon Musk took to Twitter to proclaim that the deal involving his proposed buyout of Twitter is β€œtemporarily on hold pending details supporting calculation that spam/fake accounts do indeed represent less than 5% of users.” πŸ™ƒ

The controversial tweet linked to a Reuters report stating that Twitter estimated less than 5% of the platform’s users are fake accounts. πŸ“

Read It

An M&A Mashup

It was another busy Monday of M&A and fundraising news, so let’s quickly recap. πŸ‘‡

First up is Macy’s, which saw shares soar 20% on reports that the 165-year-old retailer is considering a buyout offer from Arkhouse Management and Brigade Capital Management. It’s unclear how the company’s board feels about the offer, but clearly, these firms have value in Macy’s real estate. Analysts speculate that the investor group may sell off real estate and spin off its e-commerce business to deliver short-term gains. However, that would come at the expense of the core retail business people know and love it for. 🏬

Read It